PACIRA BIOSCIENCES INC. - COMMON STOCK

Sevāredent Sourcing Solutions and Pacira BioSciences Collaborate to Provide Expanded Access to EXPAREL for Patients Undergoing Oral and Maxillofacial Procedures

27 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy

21 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Pacira Receives Positive CHMP Opinion for EXPAREL® for the Treatment of Postsurgical Pain in Children Aged 6 or Older

20 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Pacira BioSciences Reports Preliminary Net Product Sales of $59.1 Million for August 2022

13 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty

07 Sep 2022 06:00:01 By Nasdaq GlobeNewswire

Pacira BioSciences Reports Preliminary Net Product Sales of $50.2 Million for July 2022

10 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

NFL Alumni Association and Pacira BioSciences Team Up to Educate Athletes and Communities About Non-Opioid Options to Manage Pain

09 Aug 2022 06:30:00 By Nasdaq GlobeNewswire

Pacira BioSciences Reports Second Quarter 2022 Financial Results

03 Aug 2022 07:00:03 By Nasdaq GlobeNewswire

Pacira BioSciences to Participate in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference

02 Aug 2022 07:00:02 By Nasdaq GlobeNewswire

Pacira to Report Second Quarter 2022 Financial Results on Wednesday August 3, 2022

27 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

Pacira BioSciences Reports Preliminary Second Quarter 2022 Revenue of $169.4 Million

14 Jul 2022 06:30:00 By Nasdaq GlobeNewswire

National Safety Council and Pacira BioSciences Partner to Launch an Employee-Based Program Focused on Opioid Use and Misuse

16 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $46.0 Million for May 2022

14 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Pacira BioSciences to Participate in Fireside Chat at the Jefferies Healthcare Conference

02 Jun 2022 07:00:02 By Nasdaq GlobeNewswire

Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $45.8 Million for April 2022

12 May 2022 07:00:02 By Nasdaq GlobeNewswire

Pacira BioSciences to Present at Two Healthcare Conferences in May

10 May 2022 07:00:02 By Nasdaq GlobeNewswire

Pacira BioSciences Reports First Quarter 2022 Financial Results

04 May 2022 07:00:02 By Nasdaq GlobeNewswire

Pacira to Report First Quarter 2022 Financial Results on Wednesday May 4, 2022

27 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Pacira BioSciences Reports Preliminary Revenues of $157.4 to $158.4 Million for the First Quarter of 2022

12 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Pacira BioSciences to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference

05 Apr 2022 07:00:02 By Nasdaq GlobeNewswire